Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Cardiac Conduction System Disease

Cardiac Conduction System Disease

Cardiac Conduction System Diseases: Explore the latest advances in this critical area of cardiac research.
PubCompare.ai's AI-powered platform helps you easily locate relevant protocols from literature, pre-prints, and patents.
Leverage AI-driven comparisons to identify the most effective treatments and products, optimizing your research with cutting-edge tools.
Discover the future of cardiac care and unlock the power of data-driven insights.
Deepen your understanding of these complex disorders and drive breakthroughs in patient outcomes.

Most cited protocols related to «Cardiac Conduction System Disease»

1
Predicting Survival for Kidney Cancer Patients
For the data example, we used Surveillance Epidemiology and End Results (SEER) data that had been linked to Medicare claims data.[23 ] The SEER database is maintained by the National Cancer Institute and currently has data on demographic and tumor characteristics about incident cancer cases in approximately 25% of the United States. SEER data can be linked to Medicare claims to find additional information on treatment and comorbidities. Medicare covers almost all individuals over 65 years old in the SEER database. Fee-for-service claims from Medicare Part A and Part B provide a record of treatments obtained before and after cancer diagnosis.
We included cases over 66 years old diagnosed from 1995-2007 with surgically-treated early stage (localized) kidney cancer in the SEER-Medicare data. We restricted the sample to those over 66 years old so that individuals would have at least one year pre-diagnosis Medicare claims data. We chose a group with localized kidney cancer as such tumors are often slow growing, and many patients are likely to die from their comorbidities rather than the cancer itself.[24 (link)]
We coded the Charlson Comorbidity Index using an algorithm for claims data [23 ]. We used a similar algorithm to identify Elixhauser measures [25 ]. Since everyone in the sample had a kidney cancer diagnosis, cancer diagnosis was not used to calculate the scores. Also, the Elixhauser program does not calculate the cardiac arrhythmia indicator due to Dr. Elixhauser’s “concerns about reliability.”[25 ] To be considered a comorbidity and not a “rule-out” diagnosis, two Medicare claims at least 30 days apart had to be found in the one year period prior to kidney cancer diagnosis.
For comparison purposes, we examined the discriminative ability of using the Charlson and Elixhauser scores and the respective individual comorbidities in Cox proportional hazards regressions. In all models we included the following baseline characteristics: age at diagnosis, year of diagnosis, diameter of the tumor, sex, race/ethnicity (five categories: Hispanic or non-Hispanic black, white, Asian, other), and marital status (married/not married). We used Harrell’s concordance index (C-index) to compare the two methods of incorporating comorbidities.[26 ] We examine the concordance statistic as it is often of interest to health service researchers. A C-index of 0.5 indicates that a model is not useful in predicting who will have longer survival among pairs of individuals, while a value of 1.0 indicates that the model has perfect discriminatory power.
Austin S.R., Wong Y.N., Uzzo R.G., Beck J.R, & Egleston B.L. (2015). Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser score work. Medical care, 53(9), e65-e72.
Publication 2013
Asian Persons Cancer of Kidney Cardiac Conduction System Disease Diagnosis Ethnicity Hispanics Malignant Neoplasms Neoplasms Operative Surgical Procedures Patients
2
Computational Modeling of Canine Ventricular Fiber Orientation
The LDRB algorithm was tested in a MRI-based computational model of the structurally normal canine ventricles. The geometry and DTI-derived fiber orientation of the model were constructed using the methods of Vadakkumpadan et al.34 (link) applied to MRI and DTI data collected by Helm et al.16 (link) To generate the same model but with LDRB fiber orientation, the input functions in Eqs. (1)–(4) were optimized so that the mean angle between the LDRB and DTI-derived fiber orientations was minimal. The optimal values for the input parameters αendo, αepi, βendo and βepi of the LDRB algorithm were determined by varying each parameter in the range of ±90° in intervals of 5°, then choosing the parameter combination that produced the smallest mean angle (θmean) between the LDRB and DTI vectors (F  S  T) calculated over the total number of elements in Ω(Nelem). Since fiber orientation is bi-directional, θmean was calculated as
θmean(x→i)=1Nelem∗∑i=0Nelemcos−1(|x→iLDRB·x→iDTI‖x→iLDRB‖‖x→iDTI‖|),
x→=[F,S,T]
Membrane kinetics in this model of the canine ventricles were described by the Greenstein–Winslow myocyte model.12 (link) Orthotropic tissue conductivities of 0.5 (S/m) along F, 0.3 (S/m) along T, and 0.16 (S/m) along S were assigned to produce conduction velocities within the range of 20–80 cm/s as observed in experiments.8 (link) Monodomain simulations were performed with the model of the canine ventricles using the Cardiac Arrhythmia Research Package37 (link) (CardioSolv LLC) running on 16 compute nodes, each with four Dual Core AMD Opteron processors (Model 2222) and 8GB of memory. All simulations were executed with a 10 µs time step.
Bayer J.D., Blake R.C., Plank G, & Trayanova N.A. (2012). A Novel Rule-Based Algorithm for Assigning Myocardial Fiber Orientation to Computational Heart Models. Annals of biomedical engineering, 40(10), 2243-2254.
Publication 2012
Canis familiaris Cardiac Conduction System Disease Cloning Vectors Electric Conductivity Fibrosis Heart Ventricle Kinetics Memory Muscle Cells Tissue, Membrane Tissues
3
Clinical Severity Scale for Niemann-Pick Disease
This study was approved by the National Institute of Child Health and Human Development Institutional Review Board. Consent and, when appropriate, assent were obtained. A clinical severity scale was developed to ascertain clinical symptoms in nine major and eight minor clinical areas (Table I). Four of the domains (Ambulation, Fine Motor Skills, Speech, and Swallowing) were modified from the disability scale developed by Iturriaga et al [Iturriaga et al., 2006 (link)]. The scoring of each domain was designed to allow a score to be derived from a comprehensive clinical evaluation. A Likert-like scale was used to assign nine major domain scores of 0–5 and eight minor domain scores of 0–2. Clinical experience was used to weight the various scales. Summation of all 17 domains yielded total possible scores that range from 0–61, with a higher score indicating more severe clinical impairment. A comprehensive medical history form was developed to document both the clinical history of current patients and to serve as a guide in extraction of data from medical records. To be scored, seizures, cataplexy, and narcolepsy had to be definitive and not questionable. For the swallowing domain, one point was scored if the patient had a history of cough while eating. Additional points were added if the patient had intermittent or consistent dysphagia with either liquids or solids. Hearing loss refers to sensorineural hearing loss and not hearing loss secondary to conductive defects. The diagnosis of NPC was established by either biochemical testing or mutation analysis. All patients have NPC1 by either molecular or complementation group testing. Two patient groups were studied. The first group consisted of 18 NPC patients (current cohort) who were enrolled in an observational study at the National Institutes of Health Clinical Center (NIH CC) between August 2006 and September 2007 (Table II). The second patient cohort consisted of 19 NPC patients (historical cohort) for whom we had sufficient medical records to generate at least three scores at different time points. Medical records were reviewed for 36 patients followed at the NIH CC by other investigators between 1972 and 2005. Of the 36 previous NIH CC patients with a diagnosis of NPC, 16 patients had three or more NIH admissions with adequate documentation to generate a severity score. Of the current patients, patient 1 had previous NIH admissions for which records were available and patients 13 and 15 had sufficient outside medical records from which we could derive longitudinal data.
Yanjanin N.M., Vélez J.I., Gropman A., King K., Bianconi S.E., Conley S.K., Brewer C.C., Solomon B., Pavan W.J., Arcos-Burgos M., Patterson M.C, & Porter F.D. (2010). Linear Clinical Progression, Independent of Age of Onset, in Niemann-Pick Disease, type C. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 153B(1), 132-140.
Publication 2009
Cardiac Conduction System Disease Cataplexy Cough Deglutition Disorders Diagnosis Disabled Persons Ethics Committees, Research Hearing Impairment Motor Skills Mutation Narcolepsy Niemann-Pick Disease, Type C1 Patients Seizures Sensorineural Hearing Loss Speech
4
COPD Randomized Trial Inclusion Criteria
Patients were randomised if they met the following main inclusion criteria: outpatients aged ≥40 years with a history of moderate to very severe COPD (GOLD stage 2–4) [23 ]; post-bronchodilator FEV1 <80% of predicted normal; post-bronchodilator FEV1/forced vital capacity (FVC) <70%; current or ex-smokers with a smoking history of >10 pack–years.
Patients with a significant disease other than COPD were excluded from the trials. Other exclusion criteria included: clinically relevant abnormal baseline laboratory parameters or a history of asthma; myocardial infarction within 1 year of screening; unstable or life-threatening cardiac arrhythmia; known active tuberculosis; clinically evident bronchiectasis; cystic fibrosis or life-threatening pulmonary obstruction; hospitalised for heart failure within the past year; diagnosed thyrotoxicosis or paroxysmal tachycardia; previous thoracotomy with pulmonary resection; regular use of daytime oxygen if patients were unable to abstain during clinic visits; or currently enrolled in a pulmonary rehabilitation programme (or completed in the 6 weeks before screening).
Patients with moderate or severe renal impairment (creatinine clearance ≤50 mL·min−1) were not excluded from the study but were closely monitored by the investigator.
Both studies were performed in accordance with the Declaration of Helsinki, International Conference on Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice and local regulations. The protocols were approved by the authorities and the ethics committees of the respective institutions, and signed informed consent was obtained from all patients.
Buhl R., Maltais F., Abrahams R., Bjermer L., Derom E., Ferguson G., Fležar M., Hébert J., McGarvey L., Pizzichini E., Reid J., Veale A., Grönke L., Hamilton A., Korducki L., Tetzlaff K., Waitere-Wijker S., Watz H, & Bateman E. (2015). Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). The European Respiratory Journal, 45(4), 969-979.
Publication 2015
Airway Obstruction Asthma Bronchiectasis Bronchodilator Agents Cardiac Conduction System Disease Chronic Obstructive Airway Disease Clinic Visits Conferences Creatinine Cystic Fibrosis Ex-Smokers Forced Vital Capacity Gold Heart Failure Institutional Ethics Committees Lung Myocardial Infarction Outpatients Oxygen Patients Rehabilitation Renal Insufficiency Tachycardia, Paroxysmal Thoracotomy Thyrotoxicosis Tuberculosis
5
Defining Chronic Medical Conditions Cohort
In order to be considered as cases, individuals were required to have a history of at least one of 16 common chronic medical conditions. We selected conditions based on their clinical relevance and burden, both in terms of cost and outcome (e.g. attributable deaths) as described in previous literature [1 -4 ,24 ,39 ,40 ]. These 16 conditions included: arthritis (excluding rheumatoid arthritis), hypertension, asthma, depression, diabetes, cancer, chronic coronary syndrome (CCS), cardiac arrhythmia, osteoporosis, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), renal failure, dementia, rheumatoid arthritis, stroke and acute myocardial infarction (AMI). While this represents a small number of possible conditions experienced by individuals, it captures many of the most substantial conditions from a population-based epidemiological perspective. Six of these conditions (AMI, asthma, CHF, COPD, hypertension, diabetes) were defined based on previously validated population-derived ICES cohorts [31 (link)-37 (link)]. For the conditions where a derived ICES cohort did not exist, we adopted a similar approach to the derivation algorithms (i.e. at least one diagnosis recorded in acute care, or two diagnoses recorded in physician records within a two-year period) to define the remaining chronic conditions: cancer, cardiac arrhythmia, chronic coronary syndrome, dementia, depression, arthritis (excluding rheumatoid arthritis), osteoporosis, renal failure, rheumatoid arthritis, and stroke. The full set of diagnostic codes used to define the conditions is included as Additional file 1. Multimorbidity was defined as the co-occurrence of two or more of these conditions.
Koné Pefoyo A.J., Bronskill S.E., Gruneir A., Calzavara A., Thavorn K., Petrosyan Y., Maxwell C.J., Bai Y, & Wodchis W.P. (2015). The increasing burden and complexity of multimorbidity. BMC Public Health, 15, 415.
Full text: Click here
Publication 2015
Arthritis Asthma Cardiac Conduction System Disease Cerebrovascular Accident Chronic Condition Chronic Obstructive Airway Disease Congestive Heart Failure Dementia Diabetes Mellitus Diagnosis Heart High Blood Pressures Ice Kidney Failure Malignant Neoplasms Myocardial Infarction Osteoporosis Physicians Rheumatoid Arthritis Syndrome

Most recents protocols related to «Cardiac Conduction System Disease»

1
Asthma Exercise Intervention Study
Subjects will be included if they have a clinical diagnosis of asthma, have at least 18 years old, have the desire of take part in the study, and the ability to understand and sign the informed consent. Exclusion criteria include: smokers, diagnosis of other respiratory disease; occurrence of an asthma exacerbation or respiratory tract infection in the last four weeks; acute myocardial infarction in the last six months; cardiac arrhythmia with a IIIb or superior grade in Lown scale; gait disorders due to neuro-muscle-skeletal system problems; comorbidities that implies reduced ability to exercise (e.g., severe anaemia, electrolyte imbalance, hyperthyroidism) [28 (link), 29 ]. Subjects that are already engaging in exercise sessions of more than 30 minutes per day with a moderate or vigorous intensity; participated in a pulmonary rehabilitation program in the last three months [30 (link)], and are pregnant and lactating women will be excluded. In addition, subjects that present contraindications to perform cardiovascular exercise, following the American Heart Association [31 (link)] and to perform the 6MWT following the American Thoracic Society / European Respiratory Society (ATS/ERS) [32 (link)] criteria, will be excluded too.
Vilanova-Pereira M., Jácome C., Rial Prado M.J., Barral-Fernández M., Blanco Aparicio M., Fontán García-Boente L, & Lista-Paz A. (2023). Effectiveness of nordic walking in patients with asthma: A study protocol of a randomized controlled trial. PLOS ONE, 18(3), e0281007.
Full text: Click here
Publication 2023
Anemia Asthma Cardiac Conduction System Disease Cardiovascular System Diagnosis Diagnostic Techniques, Respiratory System Electrolytes Europeans Hyperthyroidism Lung Myocardial Infarction Rehabilitation Respiratory Rate Respiratory Tract Infections Skeletal Muscles Woman
2
Myocardial Infarction and Heart Failure Outcomes
Our myocardial infarction (MI) definitions followed the most recent universal definition of MI [15 (link)]. Symptomatic heart failure (HF) was defined, according to the NYHA classification, as being in a class of ≥3. Revascularization was defined as any repeat PCI in a target vessel or coronary artery bypass graft (CABG) in a target vessel for lesions with a stenosis of ≧70%. Cardiovascular (CV) mortality was defined as death due to MI, cardiac arrhythmia, or HF. All-cause mortality was defined as death from any cause. Recurrent MI was defined as acute MI occurring 1 month after the index MI. Complete revascularization was defined as the absence of any angiographic significant stenosis (>70%) in all three epicardial coronary arteries with a diameter of at least 2.5 mm after PCI.
Fang H.Y., Fang Y.N., Chen Y.C., Sheu J.J, & Lee W.C. (2023). The Impact of Complete Revascularization in Symptomatic Severe Left Ventricular Dysfunction between Coronary Artery Bypass Graft and Percutaneous Coronary Intervention. Cardiology Research and Practice, 2023, 9226722.
Full text: Click here
Publication 2023
Angiography Artery, Coronary Blood Vessel Cardiac Conduction System Disease Cardiovascular System Congestive Heart Failure Coronary Artery Bypass Surgery Myocardial Infarction Stenosis
3
Prevalence of CVD in Saudi Arabian T2DM Patients
CAPTURE, a non-interventional and cross-sectional study, was carried out at 214 centers across 13 countries, from December 2018 until September 2019. The study design has been reported previously in the primary CAPTURE study, where the global findings have been detailed.21 (link)
 The focus of this report is the findings from Saudi Arabia.
The study was carried out in accordance with the Declaration of Helsinki and the International Society for Pharmacoepidemiology Good Pharmacoepidemiology Practices.22 (link),23 (link)
 Informed consent was obtained from all patients prior to taking part in the study; the clinical research ethics committees approved the study protocol and informed consent form (Appendix 1).
Study site selection was advised by local medical affairs specialists who, based on desk research and years of liaising with healthcare professionals, provided information on the types of care available in Saudi Arabia (such as primary and secondary care), as well as on the different kinds of professionals that provide diabetes care (such as primary care practitioners, endocrinologists, diabetologists, and cardiologists). Geographical spread of sites and the division of patients being treated at private (namely, Specialized Medical Centers and Dallah Hospitals, Riyadh) and public centers (namely, all other sites) were also considered. Based on this information, the contract research organization selected the final participating sites, which were approved by the sponsor. Sites were selected to be as representative as possible of the country as a whole to try to limit selection bias. The sites chosen were: Alhada Armed Forces Hospital, Al Hada; King Saud University Medical City, King Saud University, Riyadh; Specialized Medical Centre Hospital, Riyadh; King Abdulaziz University Hospital, Jeddah; King Abdulaziz Hospital for National Guard, Al Ahsa; Diabetes and Endocrinology Center-Buraidah, Buraidah; Dallah Hospital, Riyadh.21 (link)
As outlined in the primary publication,21 (link)
 patients 18 years of age or older who had a diagnosis of T2DM ≥180 days prior to the start of the study were enrolled over a 90-day period. Exclusion criteria included diagnosis of type 1 diabetes or congenital heart disease or malformation, and mental incapacity or language barriers that prevented an appropriate understanding of what the study entailed.
Data were collected by physicians or appropriately qualified delegates using standardized electronic case report forms, which were then transferred to a central database. Relevant data were extracted from patients’ medical records. The data collected included information regarding the patients’ overall health status (such as medical history and clinical parameters), demography and use of CV medication or GLAs. If there was no information relating to certain medical histories in their records (such as neuropathy, nephropathy, or retinopathy), patients were asked if they had been previously diagnosed with them.
Patients were categorized as having established CVD if their medical records indicated the diagnosis of any of the following conditions: aortic disease, cardiac arrhythmia or conduction abnormalities, carotid artery disease, cerebrovascular disease, coronary heart disease, heart failure, or peripheral artery disease. Patients were categorized as having ASCVD if they had any of the listed conditions: cerebrovascular disease, coronary heart disease, peripheral artery disease, or carotid artery disease. Full definitions for each of the above CVD subtypes are shown in Appendix 2.
To calculate the sample size, the prevalence of those with T2DM and CVD was assumed to be 25-40% and a sample size of 800 was selected to result in a precision of ±2-3% points of the calculated CVD prevalence.
Alguwaihes A.M., Alhozali A., Yahia M.M., Abdel-Nabi T., Hassan Hatahet M., Albalkhi N.I, & Al Sifri S. (2023). The prevalence of cardiovascular disease in adults with type 2 diabetes mellitus in Saudi Arabia - CAPTURE study. Saudi Medical Journal, 44(1), 57-66.
Full text: Click here
Publication 2023
Aortic Diseases Cardiac Conduction System Disease Cardiologists Carotid Artery Diseases Cerebrovascular Disorders Congenital Abnormality Congenital Heart Defects Congestive Heart Failure Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Diagnosis Electric Conductivity Endocrinologists Ethics Committees, Research Health Care Professionals Heart Disease, Coronary Kidney Diseases Military Personnel Patients Peripheral Arterial Diseases Pharmaceutical Preparations Physicians Primary Health Care Retinal Diseases Secondary Care Specialists System, Endocrine
4
Cardiovascular Disease Outcomes Protocol
We examined the following outcomes: all-cause mortality and a composite CVD event consisting of a first event of either CVD mortality, non-fatal myocardial infarction, non-fatal stroke, revascularisation or amputation within the study period. CVD mortality included death due to acute myocardial infarction, heart failure, cardiac arrhythmia, stroke or death related to a cardiovascular procedure. Revascularisation included invasive coronary as well as peripheral revascularisation procedures. This clinical information was collected from death certificates, post-mortem reports, medical records, hospital discharge summaries, electrocardiographs, laboratory results, etc. and sent to two members of the expert committee for independent adjudication according to an agreed protocol. Outcomes were recorded on standard case report forms. Committee members met to reach consensus over discrepancies. After the first CVD event, the participant was censored. Inclusion date was the date the blood sample was drawn for the 5-year follow-up of the original study. For each participant, we calculated the time to all-cause mortality or the composite CVD event as appropriate, using the inclusion date until the event or the date the study ended (31 December 2014). All participants gave their informed consent. The study was performed in compliance with the Helsinki Declaration and was approved by The Central Denmark Region Committees on Health Research Ethics. Besides event information, baseline characteristics included age, sex, BMI, waist circumference, systolic and diastolic blood pressure, as well as baseline biochemical variables including haemoglobin A1c (HbA1c), creatinine, cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides. Furthermore, self-reported data included information on medication, alcohol and smoking habits, as well as information on known or former diseases, including former myocardial infarction or stroke, a diagnosis of angina or arrhythmia and former coronary intervention or surgery. We created a CVD comorbidity variable that combined the self-reported information relevant to CVD (former myocardial infarction, stroke or coronary intervention/surgery or a diagnosis of angina). A positive score in the CVD comorbidity variable indicated that the participant had experienced at least one of the above.
Gude M.F., Hjortebjerg R., Bjerre M., Charles M.H., Witte D.R., Sandbæk A, & Frystyk J. (2023). The STC2–PAPP-A–IGFBP4–IGF1 axis and its associations to mortality and CVD in T2D. Endocrine Connections, 12(3), e220451.
Publication 2023
Amputation Angina Pectoris Autopsy BLOOD Cardiac Arrhythmia Cardiac Conduction System Disease Cardiovascular System Cerebrovascular Accident Cholesterol Cholesterol, beta-Lipoprotein Committee Members Congestive Heart Failure Creatinine Diagnosis Electrocardiography Ethanol Heart Hemoglobin A, Glycosylated High Density Lipoprotein Cholesterol Myocardial Infarction Operative Surgical Procedures Patient Discharge Pharmaceutical Preparations Pressure, Diastolic Surgical Procedure, Cardiac Systole Triglycerides Waist Circumference
5
Demographic Characteristics and Comorbidities in Chronic Kidney Disease

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Alaskan Natives American Indians Asian Persons Cardiac Conduction System Disease Chest Congestive Heart Failure Creatinine Cystatin-SN Diabetes Mellitus Diagnosis EGFR protein, human Electrolytes Ethnicity Glomerular Filtration Rate High Blood Pressures Hispanics Hypothyroidism Index, Body Mass Kidney Failure Latinos Liver Diseases Lymphoma Males Malignant Neoplasms Neoplasm Metastasis Neoplasms Patients Post-gamma-Globulin

Top products related to «Cardiac Conduction System Disease»

1
Spss statistics version 21 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, China
SPSS Statistics version 21 is a statistical software package developed by IBM. It is designed for data analysis and management, providing tools for data exploration, modeling, and reporting. The software offers a range of statistical techniques and is widely used in academic and professional research settings.
2
Teneo volume scope by Thermo Fisher Scientific
Sourced in United States
The Teneo Volume Scope is a laboratory instrument designed for high-resolution 3D imaging and quantitative analysis of samples. It utilizes advanced electron microscopy technology to capture detailed, three-dimensional visualizations of specimens.
3
Pgc 1β by Jackson ImmunoResearch
Sourced in United States
Pgc-1β−/− is a lab equipment product that serves as a knockout mouse model. This model lacks the Pgc-1β gene, which is involved in the regulation of cellular metabolism and mitochondrial function.
4
Nitrocellulose filter by Merck Group
Sourced in United States, Ireland, Germany, Italy, France
Nitrocellulose filters are a type of laboratory equipment used for filtration and separation processes. They are made of a thin, porous membrane composed of nitrocellulose, which allows for the efficient capture and retention of various substances, including particles, proteins, and DNA. Nitrocellulose filters are widely used in various scientific and analytical applications, such as Western blotting, dot blotting, and immunoassays.
5
Labchart 7 by ADInstruments
Sourced in Australia, United States, New Zealand, United Kingdom, Germany, Colombia, Japan
LabChart 7 is a data acquisition and analysis software designed for recording, visualizing, and analyzing physiological signals. It provides a user-friendly interface for capturing data from various types of laboratory equipment and sensors. LabChart 7 offers tools for real-time display, analysis, and offline processing of the acquired data.
6
Em ace600 sputter coater by Leica
Sourced in Germany, Austria
The EM ACE600 is a sputter coater manufactured by Leica. It is designed to deposit thin metallic or conductive coatings on samples to enhance their conductivity for imaging in scanning electron microscopes (SEM) or other applications requiring conductive surfaces.
7
Corevalve by Medtronic
Sourced in United States, Ireland, Switzerland
CoreValve is a medical device designed for the treatment of severe aortic stenosis. It is a prosthetic heart valve that is implanted via a minimally invasive procedure to replace the patient's diseased aortic valve.
8
Magnevist by Bayer
Sourced in Germany, United States, Japan, China, United Kingdom, Jersey, Canada, Ireland
Magnevist is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) procedures. It is designed to enhance the visualization of internal body structures and improve the diagnostic capabilities of MRI scans.
9
Dionex ics 2000 by Thermo Fisher Scientific
Sourced in United States
The Dionex ICS-2000 is an ion chromatography system designed for the analysis of inorganic anions and cations. It features high-performance ion exchange separations and suppressed conductivity detection. The Dionex ICS-2000 is a compact and automated system that provides accurate and reliable results for a variety of applications.

More about "Cardiac Conduction System Disease"

Cardiac conduction system diseases, also known as arrhythmias or dysrhythmias, refer to a range of disorders that affect the electrical impulses that coordinate the beating of the heart.
These conditions can lead to irregular heartbeats, slow or fast heart rates, and other cardiac issues.
Some key subtopics in this area include: - Bradycardia: Abnormally slow heart rate, which can be caused by disorders in the sinus node, atrioventricular (AV) node, or other parts of the conduction system.
SPSS Statistics version 21 may be used to analyze data related to bradycardia. - Tachycardia: Abnormally fast heart rate, which can be caused by conditions like atrial fibrillation, ventricular tachycardia, or other arrhythmias.
Teneo Volume Scope may be used to study tachycardic episodes. - Heart block: Partial or complete blockage of electrical signals as they travel through the conduction system, leading to slow or irregular heartbeats.
Pgc-1β−/− mice have been used to study certain types of heart block. - Wolff-Parkinson-White syndrome: A condition where an extra electrical pathway between the atria and ventricles causes a rapid heart rate.
Nitrocellulose filters may be used in research related to this syndrome.
Advances in cardiac conduction system disease research are being driven by innovative tools and technologies.
LabChart 7 software can be used for high-quality data acquisition and analysis, while the EM ACE600 sputter coater facilitates the preparation of samples for electron microscopy studies.
Emerging treatments for conduction system diseases include the CoreValve system for aortic valve replacement and the use of Magnevist, a contrast agent, in cardiac MRI scans.
The Dionex ICS-2000 ion chromatography system may also be employed in related biochemical analyses.
By leveraging the power of data-driven insights from PubCompare.ai's AI-powered platform, researchers can optimize their work and drive breakthroughs in the understanding and treatment of these complex cardiac disorders, ultimately improving patient outcomes.